Compare Futu Holdings Ltd (FUTU) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Futu Holdings Ltd trades at $110.71 (market cap $15.25B), while State Street SPDR S&P Biotech ETF trades at $149.93 (market cap $10.11B). The key difference: Futu Holdings Ltd is the larger of the two by market cap, and Futu Holdings Ltd pays a 2.39% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Futu Holdings Ltd for 34 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| FUTU | XBI | |
|---|---|---|
Market Cap | $15.25B | $10.11B |
Volume | 812,567 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $199.04 | $169.55 |
52-Week Low | $89.76 | $104.99 |
Typical Hold Time | 34 Days | 37 Days |
Enterprise Value | $15.59B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Futu Holdings (FUTU) trades at $109.68, down 3.12% today, amid a bearish technical signal but strong fundamentals. Revenue grew to $22.85B in 2025 with a net income margin of 49.62%, while valuation ratios like a P/E of 10.95 suggest potential undervaluation. Recent news includes Moomoo's partnership with X and a class action lawsuit deadline, adding mixed sentiment.
The outlook is cautiously optimistic due to robust earnings growth and analyst upside targets near 33%, but risks from legal issues and competitive pressures warrant monitoring. Investors may find value if the company executes on overseas expansion, though volatility from technical bearishness persists.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
